Diğer (Uluslararası) Tamamlandı ULUSLARARASI TEŞV 4,0
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess
the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily
for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis
1 araştırmacı
Detay